PORT WASHINGTON, N.Y., September 16, 2013 — ForteBio, a division of Pall Life Sciences and a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch of the Octet® HTX system, the new flagship member of the Octet line of label-free interaction analysis systems. The Octet HTX system addresses the acute industry need for increased analysis speed and sample throughput when characterizing large numbers of therapeutic candidates.
Octet systems provide unique insights into drug-target binding interactions, insights that are used to fine-tune the affinity and specificity of drug molecules. The Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously, a capability offered by no other stand-alone label-free platform. The system offers dramatic time savings for researchers studying large panels of drug candidates, and provides innovative data analysis tools for developers of monoclonal antibodies and other biotherapeutic entities. In addition, the Octet HTX performs full 96-well plate determinations of protein concentrations in as little as 2 minutes.
“The need for higher analytical throughput is a central theme with our pharmaceutical and biopharm customers,” noted Robert Wicke, General Manager at Pall’s ForteBio Division. “We believe researchers will be delighted by the Octet HTX system. The HTX system was engineered for speed while maintaining peak performance, and will directly address critical bottlenecks in the drug development process.”
The Octet HTX system was unveiled today at the BioProcess International 2013 conference in Boston, Mass.
ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.
About Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Its membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall Life Sciences is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall Life Sciences' technologies are also used in clinical institutions and the food and beverage industries.
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
Contact Information :
Corporate Public Relations, Pall Corporation
Contact Information 2 :